Eri LM - Search Results

1

The effect of bicalutamide on prostate histology.

Eri LM, Svindland A, Tveter KJ. Eri LM, et al. Prostate. 2001 Mar 1;46(4):275-80. doi: 10.1002/1097-0045(20010301)46:4<275::aid-pros1033>3.0.co;2-2. Prostate. 2001. PMID: 11241549

2

Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia.

Eri LM, Tveter KJ. Eri LM, et al. Eur Urol. 1994;26(3):219-26. doi: 10.1159/000475384. Eur Urol. 1994. PMID: 7528662 Clinical Trial.

3

Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia.

Eri LM, Haug E, Tveter KJ. Eri LM, et al. Br J Urol. 1995 Mar;75(3):335-40. doi: 10.1111/j.1464-410x.1995.tb07345.x. Br J Urol. 1995. PMID: 7537602 Clinical Trial.

4

alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia.

Eri LM, Tveter KJ. Eri LM, et al. J Urol. 1995 Sep;154(3):923-34. J Urol. 1995. PMID: 7543612 Review.

5

A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia.

Eri LM, Tveter KJ. Eri LM, et al. J Urol. 1993 Jul;150(1):90-4. doi: 10.1016/s0022-5347(17)35406-x. J Urol. 1993. PMID: 7685428 Clinical Trial.

6

Morphometry of benign prostatic hyperplasia during androgen suppressive therapy. Relationships among epithelial content, PSA density, and clinical outcome.

Svindland A, Eri LM, Tveter KJ. Svindland A, et al. Among authors: eri lm. Scand J Urol Nephrol Suppl. 1996;179:113-7. Scand J Urol Nephrol Suppl. 1996. PMID: 8908676 Clinical Trial.

7

Can prostate epithelial content predict response to hormonal treatment of patients with benign prostatic hyperplasia?

Eri LM, Svindland A. Eri LM, et al. Urology. 2000 Aug 1;56(2):261-5. doi: 10.1016/s0090-4295(00)00629-4. Urology. 2000. PMID: 10925090

8

Effects of bicalutamide and leuprolide on prostate-specific antigen (PSA), acid phosphatase (ACP) and prostatic acid phosphatase (PAP) in men with benign prostatic hyperplasia (BPH).

Eri LM, Tveter KJ. Eri LM, et al. Prostate Cancer Prostatic Dis. 2001;4(3):173-177. doi: 10.1038/sj.pcan.4500504. Prostate Cancer Prostatic Dis. 2001. PMID: 12497037

9

Role of serum response factor expression in prostate cancer biochemical recurrence.

Prencipe M, Fabre A, Murphy TB, Vargyas E, O'Neill A, Bjartell A, Tasken KA, Grytli HH, Svindland A, Berge V, Eri LM, Gallagher W, Watson RW. Prencipe M, et al. Among authors: eri lm. Prostate. 2018 Jul;78(10):724-730. doi: 10.1002/pros.23516. Epub 2018 Apr 2. Prostate. 2018. PMID: 29608018

10

Measuring the quality of life of patients with benign prostatic hyperplasia. Assessment of the usefulness of a new quality of life questionnaire specially adapted to benign prostatic hyperplasia patients.

Eri LM, Tveter KJ. Eri LM, et al. Eur Urol. 1992;21(4):257-62. doi: 10.1159/000474853. Eur Urol. 1992. PMID: 1281101

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters